RTP Mobile Logo

Sunday, June 3, 2018, Chicago, IL, 7:00 PM – 9:30 PM

Beyond the Guidelines: Investigator Perspectives on Current Clinical Issues and Ongoing Research in the Management of Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma

Event Details

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

6:30 PM – 7:00 PM (Central Time) — Registration and Dinner Buffet
7:00 PM – 9:30 PM (Central Time) — Educational Meeting

Meeting Room:
Grand Ballroom (Level 2)

There is no registration fee for this event. However, preregistration is advised as seating is limited.  
Stephen Maxted Ansell, MD, PhD
Professor of Medicine
Division of Hematology
Mayo Clinic
Rochester, Minnesota

Matthew S Davids, MD, MMSc
Associate Director, Center for Chronic Lymphocytic Leukemia
Assistant Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Rafael Fonseca, MD
Getz Family Professor of Cancer
Chair, Department of Internal Medicine
Mayo Clinic Arizona
Scottsdale, Arizona

Paul G Richardson, MD
Clinical Program Leader
Director of Clinical Research
Jerome Lipper Multiple Myeloma Center
Department of Medical Oncology
Dana-Farber Cancer Institute
RJ Corman Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Laurie H Sehn, MD, MPH
Centre for Lymphoid Cancer
BC Cancer Agency and University of British Columbia
Vancouver, British Columbia, Canada

Anas Younes, MD
Chief, Lymphoma Service
Memorial Sloan Kettering Cancer Center
New York, New York

Neil Love, MD
Research To Practice
Miami, Florida

Not an official event of the 2018 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or the Conquer Cancer Foundation.

This activity is supported by educational grants from AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech BioOncology, Gilead Sciences Inc and Seattle Genetics.


Meeting Format and Agenda

To begin each module, results of interactive audience polling using networked iPads will be juxtaposed with the findings from a comprehensive survey comprising case-based and related management questions completed by 25 tumor-specific clinical investigators prior to the meeting. Each faculty member will then deliver a presentation reviewing recently published research data and ongoing clinical trials related to the topics and questions addressed via the surveys. After each presentation, moderated panel discussion will take place to generate other relevant perspectives and dialogue.

MODULE 1: Induction and Maintenance Therapy for Multiple Myeloma (MM) — Dr Fonseca

  • Longer-term follow-up and emerging data with novel front-line triplets (eg, RVD lite, KRd)
  • Results from the Phase III ALCYONE study and FDA approval of daratumumab with bortezomib, melphalan and prednisone for newly diagnosed, transplant ineligible patients
  • Other ongoing trials evaluating novel agents (eg, elotuzumab, ixazomib, panobinostat) as a component of induction therapy
  • Clinical trial evidence supporting maintenance and consolidation therapy for patients with normal- and high-risk disease
  • Available platforms, clinical significance and current nonresearch applications for minimal residual disease (MRD) assessment in MM

MODULE 2: Management of Relapsed/Refractory (R/R) MM; Novel Strategies Under Active Investigation — Dr Richardson

  • Impact of prior therapeutic exposure, disease-free interval, cytogenetic status and symptomatology on therapeutic decision-making
  • Optimal selection, sequencing and combining of available agents for patients with R/R disease
  • Early efficacy and safety results with BCMA (B-cell maturation antigen)-targeted chimeric antigen receptor (CAR) T-cell therapy in MM
  • Ongoing investigation of venetoclax and potential clinical role, particularly in patients with t(11;14)

MODULE 3: Chronic Lymphocytic Leukemia (CLL) — Dr Davids

  • Utility of existing and emerging biomarkers (eg, del[17p], IGHV mutations, TP53 mutations, complex karyotype, MRD) and implications for clinical decision-making
  • Key efficacy and safety findings from the Phase III MURANO trial comparing venetoclax/rituximab to bendamustine/rituximab for R/R CLL; potential role of venetoclax for patients without del(17p)
  • Mechanism of action, early safety and activity and ongoing Phase III investigation of acalabrutinib in CLL
  • Emerging research information and ongoing evaluation of novel combination approaches (eg, venetoclax/ibrutinib, ibrutinib/FCR) for untreated or R/R CLL

MODULE 4: Hodgkin Lymphoma (HL) — Dr Younes

  • Results from the Phase III ECHELON-1 trial evaluating brentuximab vedotin (BV) with AVD versus ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine) as front-line therapy for advanced classical HL; clinical implications of the recent FDA approval of BV and AVD as first-line therapy
  • Indications for and practical considerations with the use of BV as consolidation therapy after autologous stem cell transplant
  • Response rates, durability of responses and long-term outcomes in patients receiving anti-PD-1/PD-L1 antibodies for R/R HL
  • Available data with and ongoing investigation of anti-PD-1/PD-L1 antibody therapy in combination with other targeted and immunotherapeutic agents (eg, BV, anti-CTLA-4 antibodies)

MODULE 5: Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Ansell

  • Similarities and differences among available and developmental CAR T-cell platforms with established efficacy in DLBCL
  • FDA approvals and current clinical roles of axicabtagene ciloleucel and tisagenlecleucel for DLBCL and other aggressive lymphomas
  • Patient selection and practical considerations for the administration of CAR T-cell therapy
  • Available research information with and ongoing investigation of lenalidomide and ibrutinib for newly diagnosed and R/R DLBCL

MODULE 6: Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL) — Dr Sehn

  • FDA approval and integration of obinutuzumab-based induction and maintenance therapy for previously untreated FL
  • Clinical and research implications of the Phase III RELEVANCE trial results in newly diagnosed patients; current clinical role of the “R-squared” regimen of lenalidomide/rituximab for R/R disease
  • Mechanism of action of, available data with and FDA approval of copanlisib for R/R FL
  • Available and emerging research information with novel agents as a component of induction and/or post-transplant maintenance therapy in MCL
  • Clinical research data supporting the recent FDA approval of acalabrutinib in MCL; patient selection for this approach in routine practice

CE Information

Target Audience:
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of hematologic cancers.

Learning Objectives and Goals:
At the conclusion of this activity, participants should be able to:

  • Individualize the selection and sequence of systemic therapy for patients with newly diagnosed and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), considering clinical presentation, biomarker profile and psychosocial status.
  • Consider existing and emerging clinical research data in the formulation of therapeutic recommendations for patients with newly diagnosed and R/R diffuse large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma.
  • Incorporate new therapeutic strategies into the best-practice management of newly diagnosed and R/R Hodgkin lymphoma (HL).
  • Customize the use of induction, consolidation and maintenance therapeutic approaches for patients with multiple myeloma (MM) in the post-transplant and nontransplant settings, considering patient- and disease-related factors, including cytogenetic profile.
  • Consider published research data and other clinical factors in the best-practice selection, sequencing or combining of available therapeutic agents in the nonresearch care of patients with R/R MM.
  • Compare and contrast the mechanisms of action, efficacy and safety of approved and investigational immunotherapeutic approaches (eg, immune checkpoint inhibitors, chimeric antigen receptor-directed T-cell therapy) for the treatment of HL, non-Hodgkin lymphoma (NHL), CLL and MM to determine the current and/or potential utility of each in clinical practice.
  • Design and implement a plan of care to recognize and manage side effects and toxicities associated with existing and recently approved systemic therapies in the management of HL, NHL, CLL and MM to support quality of life and continuation of treatment.
  • Assess the ongoing clinical trials evaluating other novel investigational approaches for HL, NHL, CLL and MM, and obtain consent from appropriate patients for study participation.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

This activity is supported by educational grants from AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech BioOncology, Gilead Sciences Inc and Seattle Genetics.


Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Meeting Room:
Grand Ballroom (Level 2)

The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center.



Thank you for your interest in our educational program.  At this time, online preregistration is closed. However, seats are still available for the conference. Onsite registration will be open starting at 6:30 PM (Central Time) on Sunday, June 3rd. If you are interested in attending, please visit our registration desk in the Grand Ballroom foyer located on the second level of the Hilton Chicago (720 Michigan Avenue, Chicago, IL).

Please note, onsite registrant seating will be prioritized for healthcare professionals directly involved in the treatment of patients. If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153.